What I Learned Making 22 Healthcare Startup Investments as a Physician-Scientist: The Other 5% of Your Money
 |
 |
<!–
[EDITOR’S NOTE: The White Coat Investor espouses an investing philosophy that says you can get wealthy and/or reach financial independence by being slow, steady, and consistent with your financial plan. As WCI founder Dr. Jim Dahle has said, investing should be boring. But we also know that some investors like a little excitement in their portfolio. That’s why we occasionally write about topics like crypto, options, baseball cards, and collectibles. We acknowledge that these alternative strategies can be used by a smart investor, but we maintain they should not use more than 5% of their portfolio in these so-called “play money” investments.
In this occasional series, titled The Other 5% of Your Money, we explore these alternative strategies. If you take part in alternative investments (anything from investing in futures, high-end art, short selling, sports gambling, gold, etc.) and you’re interested in writing a guest post for WCI, either submit an article through our Guest Post Policy page or email content@whitecoatinvestor.com. Show us how you can make 5% of your money work for you, even if it’s something that goes against the boring investor’s strategy.]
Seven years ago, I wrote my first check into a healthcare startup. I was an internal medicine-trained physician-scientist with over 100 peer-reviewed publications—mostly in gastroenterology outcomes research—and zero venture capital experience. I had no fund, no institutional backing, and no formal training in private market investing. What I did have was a hypothesis: that a physician who understands clinical workflows, regulatory pathways, and reimbursement mechanics would make better healthcare investment decisions than a generalist financier learning those things from consultants.
That hypothesis came from years of outcomes research. I kept seeing the same disconnect—a wide gap between where the real clinical needs are and where healthcare investment dollars actually get spent. Capital was flowing into solutions that looked good on pitch decks but missed fundamental clinical, regulatory, or reimbursement realities. Closing that gap became PhysicianEstate—a healthcare-focused venture capital firm I built to invest at the pre-seed and seed stage across digital health, biotech, medical devices, and therapeutics. Today, it’s my full-time role as general partner.
Since then, I’ve made 22 investments across special purpose vehicles and angel checks in healthcare startups for digital health, health tech, biotech, medical devices, and therapeutics. The portfolio currently sits at 2.16x gross TVPI (Total Value to Paid-In Capital) at a median investment age of 3.5 years. It’s roughly a 25% annualized gross return. Zero positions have been written down to date, though I fully expect that to change as the portfolio matures. Early-stage loss ratios typically settle in the 20%-40% range for pre-seed and seed portfolios.
I’m sharing these numbers not to pitch anything, but because I think the physician community deserves an honest, inside look at what healthcare venture investing actually looks like—the edge, the risks, and the things I wish I’d known before writing that first check.
The Physician Advantage Is Real, But It’s Not What You Think
When most people hear “physician investor,” they think clinical insight—the ability to evaluate whether a medical device or drug actually works. That matters, but it’s the least important part of the edge.
The real advantage is threefold, and it maps to the three gates where most healthcare startups die.
Gate #1 — Clinical Necessity
Is the problem painful enough that physicians will change their behavior? Will patients demand the solution? Will hospital systems budget for it? This isn’t a TAM (Total Addressable Market) question; it’s a workflow question. I’ve seen startups with billion-dollar addressable markets that solve problems no clinician actually cares about. The technology works. The need just doesn’t exist at the intensity required for adoption. A physician catches this in the first conversation. A generalist investor catches it 18 months and $5 million later.
Gate #2 — Regulatory Feasibility
For drugs and devices, there’s an FDA pathway—510(k), De Novo, PMA, IND-to-NDA—and the specific pathway dramatically changes the timeline, cost, and probability of success. For digital health and health tech products, the regulatory environment is different but no less complex: hospital IT security requirements, clinical validation standards, EHR integration hurdles, and payor compliance frameworks. I’ve reviewed deals where the founder’s regulatory timeline was off by three years. That’s not a rounding error. That’s the difference between a viable company and one that runs out of runway.
Gate #3 — Reimbursement Viability
Even if the product works and clears regulatory hurdles, someone has to pay for it. Is there an existing CPT code? Will CMS cover it? Will private insurers follow? Will hospitals absorb it into existing budgets, or is it a new line item that requires C-suite approval? Will patients pay out of pocket? A healthcare startup with no reimbursement pathway is a technology, not a business. Understanding reimbursement mechanics (CPT, DRG, APC, NTAP) requires healthcare system fluency that takes years to develop. Most generalist VCs outsource this to consultants. At my venture firm, we do it in-house because our network includes physicians who navigate these systems every day.
These three gates represent the minimum diligence standard for any healthcare investment. In my experience, they are almost entirely absent from traditional venture capital due diligence, which relies heavily on market sizing, competitive mapping, and financial modeling—all of which can look excellent for a company that will ultimately fail because nobody asked the clinical questions.
More information here:
- Should Doctors Consider Angel Investing? The Other 5% of Your Money
- The Emotions Behind Short-Term Trading: The Other 5% of Your Money
The Network Is the Moat
No single physician can be an expert across every healthcare subsector. I’m internal medicine-trained. My research background is deep in GI outcomes. But healthcare investing spans cardiac devices, oncology diagnostics, digital therapeutics, surgical robotics, health tech platforms, and dozens of other domains. Each has its own clinical workflows, regulatory nuances, and reimbursement structures.
The solution was building a network of 200+ physicians across 20+ specialties embedded at research institutions like Johns Hopkins, Stanford, and Mayo Clinic. When a cardiac monitoring device comes across our pipeline, we have interventional cardiologists and electrophysiologists who can evaluate it with the same firsthand clinical authority that I bring to a GI deal. When a digital mental health platform needs validation, we have psychiatrists and behavioral health specialists who use these tools with patients daily.
This network is the fund’s most valuable asset. Every deal goes through a clinical peer review with 20+ specialist physicians before we issue a term sheet. At least 80% of reviewers need to confirm clinical necessity before we proceed. Three specific deals that I passed on after physician review have since failed to secure follow-on financing. The clinical reviewers flagged regulatory and adoption risks that weren’t visible in the financial models.
What I Got Wrong
This part matters more than the returns.
- I initially invested outside of healthcare, and I quickly learned that I wasn’t the expert. Early on, I made a handful of non-healthcare investments on behalf of our venture firm because the founders were compelling and the opportunities looked attractive on paper. Those taught me a painful lesson: our edge is entirely domain-specific. In healthcare, I can evaluate a founder’s regulatory strategy, pressure-test their reimbursement assumptions, and assess whether clinicians will actually adopt their product. Outside of healthcare, I was just another generalist writing a check based on a pitch deck. Once I recognized that, I committed to healthcare-only investing. That discipline has been one of the most important decisions I’ve made.
- I underestimated how long healthcare takes. In my first few investments, I assumed that a strong clinical thesis and a clear regulatory pathway would translate to a 3-5 year exit timeline. The reality is that healthcare moves slowly. FDA processes take longer than founders project. Hospital procurement cycles are measured in quarters, not weeks. Reimbursement negotiations with CMS can take years. If you’re investing in healthcare at the early stage, you need to be comfortable with 7-10 year hold periods for many positions. That’s a meaningful liquidity constraint that most physician investors don’t fully appreciate when they write their first check.
- I didn’t think enough about portfolio construction early on. My first 10 investments were essentially independent bets without a coherent portfolio strategy. There was no target allocation by subsector, no reserve strategy for follow-on investments, and no systematic approach to position sizing. I was investing like an angel, not a fund manager. The discipline of portfolio construction—how many positions, what reserve ratio, what stage mix—is something I only developed after making mistakes with real money.
 |
 |
<!–
Should Physicians Invest in Healthcare Venture Capital?
This is the question I get most often from colleagues, and my honest answer is: it depends on what you mean by “invest.”
As a limited partner (LP) in a healthcare-focused fund: This can make sense as a small allocation within a diversified portfolio—probably 5%-10% of your investable assets at most, and only with money you genuinely don’t need for 10+ years. The J-curve in venture is real. A venture fund’s minimum investor investment could range from $50,000-$10 million, and you will see negative returns for the first 2-3 years as management fees eat into committed capital before investments mature. Healthcare venture adds an extra layer of illiquidity risk because the exit timelines are often longer than tech. If you’re comfortable with those constraints and you believe in the thesis of the specific fund, it can be a reasonable alternative allocation.
As a direct angel investor: This is much riskier, and it requires significantly more time commitment than most physicians realize. You need to source deals, evaluate them, negotiate terms, and monitor portfolio companies—all while maintaining your clinical practice. The minimum viable check size for meaningful deal access at the pre-seed stage is typically $25,000-$100,000, and you should expect to lose your entire investment in any individual company. Diversification across 15-20+ positions is essential, and that means a minimum total commitment of $375,000-$2 million to have a statistically reasonable shot at venture-like returns (15%-25% IRR range over a 7-10 year horizon).
As a clinical advisor or diligence reviewer: This is the lowest-risk, highest-impact way for most physicians to engage with healthcare investing. Venture funds and startup accelerators are desperate for domain-expert clinical input. You can contribute meaningfully without deploying capital by reviewing deals, providing clinical validation, mentoring physician-founders, and facilitating hospital pilot introductions. Some funds compensate clinical advisors with small carried interest allocations. Others offer advisory equity in the companies themselves. This option is where I think the biggest opportunity exists for the physician community at large. Not everyone should be writing checks. But every physician has clinical expertise that the venture ecosystem badly needs and currently can’t access at scale.
More information here:
The Bottom Line
Healthcare venture capital is not a passive investment. It’s not an index fund with better returns. It is a high-risk, illiquid, long-duration asset class that requires genuine domain expertise to execute well. And even then, most early-stage funds underperform public markets on a risk-adjusted basis.
What I’ve learned over seven years is that physicians have a structural advantage in this specific asset class that no amount of financial training can replicate. The ability to evaluate clinical necessity, regulatory pathways, and reimbursement viability from firsthand experience is a genuine edge—not a marginal one. Whether that edge translates into superior long-term returns at scale is something I’m currently testing through a formal fund structure, and I’ll be honest about the results when they emerge.
What I won’t tell you is that this is easy, that the returns are guaranteed, or that every physician should be doing it. That kind of advice has no place in a community built on intellectual honesty. What I will tell you is that if you’re a physician who has ever looked at a healthcare product and thought, “I could have told them that wouldn’t work,” you’re sitting on an asset that the investment world desperately needs and consistently undervalues.
Would you ever invest in a healthcare startup? Why or why not? Do you think your expertise could make a difference in whether you make or lose money?
The post What I Learned Making 22 Healthcare Startup Investments as a Physician-Scientist: The Other 5% of Your Money appeared first on The White Coat Investor – Investing & Personal Finance for Doctors.
 |
 |
<!–
